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Hypertension-induced renal and heart failure account for 
a large proportion of chronic disease burden in the 
elderly. Antihypertensive therapy may halt the progression 
of disease. Preventing organ damage has emerged as a 
primary target for new approaches to treat hypertension. 
Signaling pathways affected by hypertension but not 
necessarily involved in blood pressure regulation itself 
have been identified as attractive new targets. 
Already in the early 1960s, a cellular stopwatch was 
described, which induced a growth arrest of normal 
somatic cells after several rounds of cell division in 
culture. In contrast, cancer cells were found to proliferate 
unlimited, implicating cellular senescence as an important 
molecular mechanism of protection against cancer. The 
molecular and cellular pathways controlling senescence 
have since been identified. The 3 "Hayflick factors" 
recording the proliferative history of cells and tissues are 
telomere shortening, accumulation of damaged DNA plus 
chromosomal damage, as well as derepression of the 
INK4a/ARF genomic locus. The molecular pathways 
mediating senescence, namely, telomere shortening and 
expression of p16INK4a through stress and aberrant 
signaling–induced senescence are dissociated, indicating 
independent pathways.[1]  
On a cellular level, a picture is emerging that tissue 
senescence is not only about the differentiated cells 
having a limited life span but also, and possibly even 
more important, reduced regenerative capacity of organ-
resident stem cells.[2] Although telomere shortening 
records cell division and finally leads to activation of the 
p53 pathway inducing apoptosis, the cell-cycle inhibitor 
p16INK4a may directly affect regenerative and proliferative 
activity of organ-resident stem cells because of inhibition 
of cyclin-dependent kinases 4 and 6. Evidence for the 
importance of this pathway was well proven concerning β-
cell precursors in pancreatic islets accounting for the 
development of late-onset diabetes type II. Also, aging 
hematopoietic stem cells demonstrate reduced lymphoid 
lineage potential.[3-5] Genetic evidence suggests that hair 
graying is the result of increased apoptosis of melanocyte 
stem cells in their niche.[6] Aging is also associated with a 
decline in neuronal progenitor cell proliferation because of 
increased expression of p16INK4a in neuronal precursor 
cells located in the subventricular zone.[7]  
It is in this context that the study by Westhoff et al [8] 
adds an intriguing new twist to the understanding of 
hypertension-induced organ damage. Although an 
association of p16INK4a expression and hypertension-
induced renal and heart failure had been described 
before, the investigators now provide compelling evidence 
of preventing premature tissue senescence by 
antihypertensive treatment. A classical blood pressure–
lowering therapy affecting vasotonus but also 
monotherapy with either spironolactone or losartan 
prevented organ damage in association with the 
downregulation of p16INK4a. These data suggest a 
possible "antiaging" effect of antihypertensive therapy. 
Whether this also implies an effect of hypertension on the 
regenerative capacity of organ-resident stem cells 
currently remains unclear. 
The authors analyzed 2 established animal models of 
hypertension, namely the deoxycorticosterone acetate-salt 
rat model and transgenic rats heterozygous for the mouse 
Ren-2gene. The latter are regarded as a valid model for 
angiotensin II–mediated hypertension. Hypertensive tissue 
injury was accompanied by a time-dependent, significant 
increase of nuclei positive for phosphorylated p38 
mitogen-activated protein kinase and p16INK4a (see 
scheme in Figure). p38 mitogen-activated protein kinase 
was analyzed because of its role in stress-induced 
p16INK4a expression: derepression of the INK4a locus by 
reactive oxygen species leading to limited functionality of 
hematopoietic stem cells is controlled by p38 mitogen-
activated protein kinase.[5] Similar observations were 
made in myocardium and cardiac vasculature. In addition, 
the investigators analyzed tissue samples from 9 patients, 
who received clinically indicated diagnostic kidney 
biopsies and had documented hypertensive renal disease. 
Again, the number of p16INK4a-positive nuclei was 
increased when expression levels were compared with a 
published, age-dependent regression analysis. 
Classical antihypertensive treatment combining 
hydrochlorothiazide, hydralazine, and reserpine or 
treatment with spironolactone prevented both 
hypertensive-induced organ damage and p16INK4a 
expression. Similarly, losartan also prevented both 
angiotensin II–induced organ damage and p16INK4a 
expression in the Ren-2gene model. In summary, p16INK4a 
expression tightly correlates with hypertensive tissue 
damage both in experimental models and human 
samples. Treatment prevents both organ damage and 
p16INK4a expression (see scheme in Figure). 
Building on these results, the question arises regarding 
whether p16INK4a expression is merely a marker of 
damage and premature senescence or an effector. 
Although the current study does not address this issue, 
several recent publications have shed light on this issue in 
other tissue compartments. At young age, expression from 
the INK4a locus is repressed by polycomb transcription 
factors. Mice lacking p16INK4a have an increased capacity 
of regeneration, whereas constitutive p16INK4a expression 
blocks endogenous regeneration.[2] This observation was 
most clearly documented again concerning the β-cells in 
the pancreatic islet but may also affect other tissue 
compartments. In addition, large population-based studies 
have found a clear association of single nucleotide 
polymorphisms in the INK4a/ARF locus and early onset 
diabetes and vascular heart disease.[2] 
Concerning hypertension-induced heart failure, the study 
by Westhoff et al [8] is also intriguing: the balance among 
apoptosis, hypertrophy, and endogenous regeneration of 
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cardiomyocytes is critical for cardiac tissue 
homeostasis.[9] Telomere shortening as the other 
senescence marker has been described as a hallmark of 
heart failure even in postmitotic cells: cardiac apoptosis in 
human heart failure was associated specifically with 
defective expression of the telomere repeat-binding factor 
TRF2, telomere shortening, and activation of the DNA 
damage checkpoint kinase, Chk2.[10] Therefore, further 
studies assessing senescence markers and their role as 
effectors in heart failure development are also needed. 
Tissue-specific stem cells have also been detected in the 
kidney, although their role in regenerating different tissue 
compartments is less clearly characterized. 
Pharmacological therapies aiming at enhancing 
endogenous regeneration by targeting the cell cycle 
machinery are under development.[11] As a note of 
caution, however, the lack of specific markers of resident 
stem cells currently limits any definite conclusion. 
Nevertheless, the current debate concerning the cellular 
and molecular pathways of senescence might also be 
valid for the understanding of hypertensive renal and 
heart disease. 
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Fig.: Schematic diagram of the senescence pathways hypothesized to be relevant for 
hypertension-induced organ damage. 
 
